Enhanced Cytoplasmic Delivery of RAGE siRNA Using Bioreducible Polyethylenimine-based Nanocarriers for Myocardial Gene Therapy

Min Jung Yang; Sook Hee Ku; Dongkyu Kim; Won Jong Kim; Hyejung Mok; Sun Hwa Kim; Ick Chan Kwon

doi:10.1002/mabi.201500213

Enhanced Cytoplasmic Delivery of RAGE siRNA Using Bioreducible Polyethylenimine-based Nanocarriers for Myocardial Gene Therapy

Min Jung Yang, Sook Hee Ku, Dongkyu Kim, Won Jong Kim, Hyejung Mok, Sun Hwa Kim, Ick Chan Kwon

Research output: Contribution to journal › Article › peer-review

8 Citations (Scopus)

Abstract

This study aims to develop bioreducible polyethylenimine (rPEI)/siRNA polyplexes with high stability, high transfection efficiency, and low cytotoxicity for efficient cytoplasmic siRNA delivery. rPEI successfully incorporated siRNA into stable and compact nanocomplexes, and the disulfide linkages in rPEI/siRNA were cleaved under reductive environments, resulting in efficient intracellular translocation and siRNA release. In this study, receptor for advanced glycation end-products (RAGE) was selected as a therapeutic target gene because it is associated with inflammatory responses in ischemia/reperfusion injury. rPEI/siRAGE exhibited high target gene silencing and low cytotoxicity in cardiomyocytes, and the treatment of rPEI/siRAGE reduced the myocardial infarction size. Bioreducible polyethylenimine (rPEI) is synthesized from low molecular weight PEI via cleavable disulfide linkages to achieve high stability, high transfection efficiency, high cytoplasmic siRNA release, and low cytotoxicity. rPEI/siRAGE polyplex can reduce RAGE expression in ischemic/reperfused myocardium, thereby leading to attenuation of myocardial infarction.

Original language	English
Pages (from-to)	1755-1763
Number of pages	9
Journal	Macromolecular Bioscience
Volume	15
Issue number	12
DOIs	https://doi.org/10.1002/mabi.201500213
Publication status	Published - 2015 Dec 1

Bibliographical note

Publisher Copyright:
© 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Keywords

RAGE
bioreducible polyethylenimine
cytoplasmic delivery
myocardial infarction
siRNA

ASJC Scopus subject areas

Biotechnology
Bioengineering
Biomaterials
Polymers and Plastics
Materials Chemistry

Access to Document

10.1002/mabi.201500213

Cite this

@article{5ab3abce681d4a5791704941f746ad17,

title = "Enhanced Cytoplasmic Delivery of RAGE siRNA Using Bioreducible Polyethylenimine-based Nanocarriers for Myocardial Gene Therapy",

abstract = "This study aims to develop bioreducible polyethylenimine (rPEI)/siRNA polyplexes with high stability, high transfection efficiency, and low cytotoxicity for efficient cytoplasmic siRNA delivery. rPEI successfully incorporated siRNA into stable and compact nanocomplexes, and the disulfide linkages in rPEI/siRNA were cleaved under reductive environments, resulting in efficient intracellular translocation and siRNA release. In this study, receptor for advanced glycation end-products (RAGE) was selected as a therapeutic target gene because it is associated with inflammatory responses in ischemia/reperfusion injury. rPEI/siRAGE exhibited high target gene silencing and low cytotoxicity in cardiomyocytes, and the treatment of rPEI/siRAGE reduced the myocardial infarction size. Bioreducible polyethylenimine (rPEI) is synthesized from low molecular weight PEI via cleavable disulfide linkages to achieve high stability, high transfection efficiency, high cytoplasmic siRNA release, and low cytotoxicity. rPEI/siRAGE polyplex can reduce RAGE expression in ischemic/reperfused myocardium, thereby leading to attenuation of myocardial infarction.",

keywords = "RAGE, bioreducible polyethylenimine, cytoplasmic delivery, myocardial infarction, siRNA",

author = "Yang, {Min Jung} and Ku, {Sook Hee} and Dongkyu Kim and Kim, {Won Jong} and Hyejung Mok and Kim, {Sun Hwa} and Kwon, {Ick Chan}",

note = "Publisher Copyright: {\textcopyright} 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.",

year = "2015",

month = dec,

day = "1",

doi = "10.1002/mabi.201500213",

language = "English",

volume = "15",

pages = "1755--1763",

journal = "Macromolecular Bioscience",

issn = "1616-5187",

publisher = "Wiley-VCH Verlag",

number = "12",

}

TY - JOUR

T1 - Enhanced Cytoplasmic Delivery of RAGE siRNA Using Bioreducible Polyethylenimine-based Nanocarriers for Myocardial Gene Therapy

AU - Yang, Min Jung

AU - Ku, Sook Hee

AU - Kim, Dongkyu

AU - Kim, Won Jong

AU - Mok, Hyejung

AU - Kim, Sun Hwa

AU - Kwon, Ick Chan

PY - 2015/12/1

Y1 - 2015/12/1

N2 - This study aims to develop bioreducible polyethylenimine (rPEI)/siRNA polyplexes with high stability, high transfection efficiency, and low cytotoxicity for efficient cytoplasmic siRNA delivery. rPEI successfully incorporated siRNA into stable and compact nanocomplexes, and the disulfide linkages in rPEI/siRNA were cleaved under reductive environments, resulting in efficient intracellular translocation and siRNA release. In this study, receptor for advanced glycation end-products (RAGE) was selected as a therapeutic target gene because it is associated with inflammatory responses in ischemia/reperfusion injury. rPEI/siRAGE exhibited high target gene silencing and low cytotoxicity in cardiomyocytes, and the treatment of rPEI/siRAGE reduced the myocardial infarction size. Bioreducible polyethylenimine (rPEI) is synthesized from low molecular weight PEI via cleavable disulfide linkages to achieve high stability, high transfection efficiency, high cytoplasmic siRNA release, and low cytotoxicity. rPEI/siRAGE polyplex can reduce RAGE expression in ischemic/reperfused myocardium, thereby leading to attenuation of myocardial infarction.

AB - This study aims to develop bioreducible polyethylenimine (rPEI)/siRNA polyplexes with high stability, high transfection efficiency, and low cytotoxicity for efficient cytoplasmic siRNA delivery. rPEI successfully incorporated siRNA into stable and compact nanocomplexes, and the disulfide linkages in rPEI/siRNA were cleaved under reductive environments, resulting in efficient intracellular translocation and siRNA release. In this study, receptor for advanced glycation end-products (RAGE) was selected as a therapeutic target gene because it is associated with inflammatory responses in ischemia/reperfusion injury. rPEI/siRAGE exhibited high target gene silencing and low cytotoxicity in cardiomyocytes, and the treatment of rPEI/siRAGE reduced the myocardial infarction size. Bioreducible polyethylenimine (rPEI) is synthesized from low molecular weight PEI via cleavable disulfide linkages to achieve high stability, high transfection efficiency, high cytoplasmic siRNA release, and low cytotoxicity. rPEI/siRAGE polyplex can reduce RAGE expression in ischemic/reperfused myocardium, thereby leading to attenuation of myocardial infarction.

KW - RAGE

KW - bioreducible polyethylenimine

KW - cytoplasmic delivery

KW - myocardial infarction

KW - siRNA

UR - http://www.scopus.com/inward/record.url?scp=84955177488&partnerID=8YFLogxK

U2 - 10.1002/mabi.201500213

DO - 10.1002/mabi.201500213

M3 - Article

C2 - 26287505

AN - SCOPUS:84955177488

SN - 1616-5187

VL - 15

SP - 1755

EP - 1763

JO - Macromolecular Bioscience

JF - Macromolecular Bioscience

IS - 12

ER -

Enhanced Cytoplasmic Delivery of RAGE siRNA Using Bioreducible Polyethylenimine-based Nanocarriers for Myocardial Gene Therapy

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this